Stem Cells in Fertility: Research Status and Limits

Key Takeaways

Stem cells are being studied as a regenerative approach for some infertility problems, especially ovarian injury, premature ovarian insufficiency, and selected uterine conditions. The science is scientifically interesting, but most stem-cell use in fertility is still experimental and should not be confused with proven fertility treatment.

Key evidence: Mesenchymal Stem Cells to Treat Female Infertility: Review · ASRM: Fertility Evaluation of Infertile Women (2021)

Stem Cells in Fertility Care

Stem cell research represents an evolving area of regenerative medicine in reproductive biology (MSC Infertility Review).

While biological interest is high, stem-cell fertility therapies remain experimental and are not approved for routine clinical use.

What Researchers Mean by Stem-Cell Treatment

Most reproductive studies focus on mesenchymal stem cells (MSCs) derived from bone marrow, adipose tissue, or umbilical cord blood.

Target research areas:

• Premature Ovarian Insufficiency (POI): Evaluating stromal cell signaling to restore follicular activity.
• Ovarian Injury: Assessing repair after chemotherapy or pelvic radiotherapy.
• Refractory Thin Endometrium: Investigating endometrial tissue regeneration.
• Severe Intrauterine Adhesions: Exploring Asherman syndrome scar modification.

Clinical Questions Still Unanswered

Before any experimental therapy can be accepted as clinical care, key scientific questions must be answered:

• Follicular Response: Does it reliably stimulate mature oocyte development?
• Embryo Yield: Does it increase usable blastocyst rates?
• Live Birth Rate: Does it demonstrate statistically significant live birth improvement in human RCTs?
• Long-Term Safety: What are the immunological and epigenetic impacts on offspring?

Main Clinical Limitations

• Inconsistent cell isolation, expansion, and preparation protocols.
• Absence of standardized administration routes (e.g., intra-ovarian injection vs. systemic infusion).
• Limited human clinical trial data with randomized control groups.
• Variable regulatory oversight across different countries.

What Patients Should Ask

If offered stem-cell treatment at a commercial clinic, patients should inquire:

• Is the procedure part of an IRB-approved clinical trial?
• Are live birth rates published in peer-reviewed journals?
• How does the protocol compare to evidence-based IVF or donor egg options?

Conclusion

Stem-cell therapies hold scientific potential for severe ovarian and uterine pathology, but remain strictly experimental until robust clinical trial data confirm efficacy and safety.

Sources

• Mesenchymal Stem Cells to Treat Female Infertility; Future Perspective and Challenges: A Review
• Mesenchymal Stem Cells Promote Ovarian Reconstruction in Mice
• ASRM: Fertility Evaluation of Infertile Women (2021)

Dr. Senai Aksoy

Dr. Senai Aksoy studied and trained in France before returning to Turkey, where he was a founding member of the ICSI team at Sevgi Hospital, Ankara — the country's first ICSI centre (1994-95) — and a co-author on the first Turkish ICSI publications produced in collaboration with the Brussels Van Steirteghem group (Human Reproduction, 1996; PMID 8671323). He helped build the IVF programme at the American Hospital Istanbul and has been running his own fertility practice since 1998.

Verified profiles: PubMed · ORCID · LinkedIn

Read full profile → Instagram YouTube

The content has been created by Dr. Senai Aksoy and medically approved.